Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients
Camus Nimmo, James Millard, Kayleen Brien, Sashen Moodley, Lucy van Dorp, Keeren Lutchminarain, Allison Wolf, Alison D Grant, Francois Balloux, Alexander S Pym, Nesri Padayatchi, Max O'Donnell, Camus Nimmo, James Millard, Kayleen Brien, Sashen Moodley, Lucy van Dorp, Keeren Lutchminarain, Allison Wolf, Alison D Grant, Francois Balloux, Alexander S Pym, Nesri Padayatchi, Max O'Donnell
Abstract
Genetic mutations linked to bedaquiline resistance were found before starting treatment and acquired during treatment in patients with drug-resistant TB and HIV in KwaZulu-Natal, South Africa. Routine bedaquiline resistance testing needs to be accelerated. http://bit.ly/2vnL4VY
Conflict of interest statement
Conflict of interest: C. Nimmo reports grants (203583/Z/16/Z) from Wellcome Trust, during the conduct of the study. Conflict of interest: J. Millard reports grants (203919/Z/16/Z) from Wellcome Trust, during the conduct of the study. Conflict of interest: K. Brien has nothing to disclose. Conflict of interest: S. Moodley has nothing to disclose. Conflict of interest: L. van Dorp has nothing to disclose. Conflict of interest: K. Lutchminarain has nothing to disclose. Conflict of interest: A. Wolf reports grants from National Institutes of Health National Institute of Allergy and Infectious Diseases, during the conduct of the study. Conflict of interest: A.D. Grant has nothing to disclose. Conflict of interest: F. Balloux has nothing to disclose. Conflict of interest: A.S. Pym is an employee of Janssen Pharmaceutica. Conflict of interest: N. Padayatchi has nothing to disclose. Conflict of interest: M. O'Donnell has nothing to disclose.
Figures
References
- World Health Organization Global Tuberculosis Report. Geneva, World Health Organization , 2019.
- Schnippel K, Ndjeka N, Maartens G, et al. . Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med 2018; 6: 699–706. doi:10.1016/S2213-2600(18)30235-2
- Borisov SE, Dheda K, Enwerem M, et al. . Effectiveness and safety of bedaquilinecontaining regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J 2017; 49: 1700387. doi:10.1183/13993003.00387-2017
- World Health Organization WHO Consolidated Guidelines on Drug-resistant Tuberculosis Treatment. Geneva, World Health Organization , 2019.
- Bloemberg GV, Keller PM, Stucki D, et al. . Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis. N Engl J Med 2015; 373: 1986–1988. doi:10.1056/NEJMc1505196
- Xu J, Wang B, Hu M, et al. . Primary clofazimine and bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2017; 61: e00239-17.
- Zimenkov DV, Nosova EY, Kulagina EV, et al. . Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region. J Antimicrob Chemother 2017; 72: 1901–1906. doi:10.1093/jac/dkx094
- Villellas C, Coeck N, Meehan CJ, et al. . Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline. J Antimicrob Chemother 2017; 72: 684–690.
- Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of mmpl5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014; 58: 2979–2981. doi:10.1128/AAC.00037-14
- Gandhi NR, Weissman D, Moodley P, et al. . Nosocomial transmission of extensively drug-resistant tuberculosis in a rural hospital in South Africa. J Infect Dis 2013; 207: 9–17. doi:10.1093/infdis/jis631
- Shah NS, Auld SC, Brust JCM, et al. . Transmission of extensively drug-resistant tuberculosis in South Africa. N Engl J Med 2017; 376: 243–253. doi:10.1056/NEJMoa1604544
- Pym AS, Diacon AH, Tang S-J, et al. . Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J 2016; 47: 564–574. doi:10.1183/13993003.00724-2015
- World Health Organization Definitions and Reporting Framework for Tuberculosis. Geneva, World Health Organization , 2014.
- World Health Organization Technical Report on Critical Concentrations for TB Drug Susceptibility Testing of Medicines used in the Treatment of Drug-resistant TB. Geneva, World Health Organization , 2018.
- Colangeli R, Jedrey H, Kim S, et al. . Bacterial factors that predict relapse after tuberculosis therapy. N Engl J Med 2018; 379: 823–833. doi:10.1056/NEJMoa1715849
Source: PubMed